3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cisplatin
131
Cetuximab
80
Radiotherapy
76
Docetaxel
59
Carboplatin
46
pembrolizumab
45
Paclitaxel
44
Fluorouracil
42
Radiotherapy, Intensity-Modulated
35
Drug Therapy
17
Radiation
14
Nivolumab
14
Gefitinib
14
Gemcitabine
13
Surgical Procedures, Operative
12
Oxaliplatin
11
Erlotinib Hydrochloride
11
130-nm albumin-bound paclitaxel
11
Pemetrexed
10
Celecoxib
10
Capecitabine
10
Bevacizumab
10
tislelizumab
9
Filgrastim
9
Amifostine
9
Albumin-Bound Paclitaxel
9
durvalumab
7
atezolizumab
7
Chemoradiotherapy
7
toripalimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Head and Neck Neoplasms
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled